uniQure (QURE) Other Non-Current Liabilities (2015 - 2026)
uniQure (QURE) posted Other Non-Current Liabilities of $18.1 million for Q2 2026, up 6.37% on a QoQ basis from $17.0 million in Q1 2026, and up 13.7% year-over-year from $15.9 million in Q2 2025.
Analysis
uniQure (QURE) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
uniQure has reported Other Non-Current Liabilities for 12 years, with the latest figure at $18.1 million in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 13.7% year-over-year to $18.1 million in Q2 2026; TTM through Jun 2026 was $18.1 million, a 13.7% increase from a year earlier, with the FY2025 full-year figure at $18.7 million, up 72.52% from the prior year.
- Other Non-Current Liabilities was $18.1 million for Q2 2026 at uniQure, up from $17.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $42.2 million in Q1 2024, with the low at $9.3 million in Q4 2022.
- Average Other Non-Current Liabilities over 5 years is $25.9 million, with a median of $23.9 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities jumped 900.97% in 2022, then tumbled 70.14% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $9.3 million in 2022, then soared by 58.51% to $14.8 million in 2023, then dropped by 26.6% to $10.9 million in 2024, then jumped by 72.52% to $18.7 million in 2025, then decreased by 3.33% to $18.1 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $18.1 million (Q2 2026), $17.0 million (Q1 2026), and $18.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.11 Mn |
| Mar 31, 2026 | 17.03 Mn |
| Dec 31, 2025 | 18.74 Mn |
| Sep 30, 2025 | 17.75 Mn |
| Jun 30, 2025 | 15.93 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 10.86 Mn |
| Sep 30, 2024 | 41.40 Mn |
| Jun 30, 2024 | 40.10 Mn |
| Mar 31, 2024 | 42.20 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 40.70 Mn |
| Jun 30, 2023 | 37.20 Mn |
| Mar 31, 2023 | 36.90 Mn |
| Dec 31, 2022 | 9.33 Mn |
| Sep 30, 2022 | 32.70 Mn |
| Jun 30, 2022 | 29.10 Mn |
| Mar 31, 2022 | 31.10 Mn |
| Dec 31, 2021 | 29.54 Mn |
| Sep 30, 2021 | 23.78 Mn |